CTRI/2018/01/011144进行中（未招募）4 期
A Prospective, Placebo Controlled Study on Caripill Tablet in Management ofChemotherapy induced Thrombocytopenia in solid tumors
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age between 18-75 years
- •2. Has, grade I to Grade III thrombocytopenia as per CTCAE criteria version 4.0
- •3. Patients undergoing chemotherapy
- •4. Patients with non-hematological malignancies
- •5. Willing and able to sign written informed consent
排除标准
- •1. Present, or history of, acute pro-myelocytic leukemia (APML), immune thrombocytopenic
- •purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or hemolytic-uremic syndrome (HUS)
- •2. Recent history of major surgery (within 2 weeks of study entry)
- •3. Currently taking, or participating in a study involving, platelet substitutes, platelet growth factors, or pharmacologic agents intended to enhance or decrease platelet hemostatic function
- •4. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study
- •5. Current HIV infection or hepatitis B virus or hepatitis C virus infections
- •6. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)
- •7. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period
- •8. Have a known diagnosis of other autoimmune diseases, established in the medical history
- •and laboratory findings with positive results for the determination of antinuclear
- •antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test
- •Patients who are deemed unsuitable for the study by the investigator
- •9. Patients with palpable splenomegaly greter than or equalto 16cm below coastal margin
- •10. Female subjects who are pregnant or breastfeeding. Women of childbearing potential are required to have a BHCG serum or urine pregnancy test performed within 7 days prior to
- •first study drug dose. A female of childbearing potential is a sexually mature woman who:
- •has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
- •naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any
- •time in the preceding 12 consecutive months). Women of child-bearing potential and men
- •must agree to use contraception prior to study entry and for the duration of study participation.
- •11. Previously enrolled in this study
研究者
相似试验
尚未招募
4 期
Clinical Trial On Papaya Leaf Extract In Cancer Patients For Increasing Platelet Let CountsCTRI/2019/01/017209Katra Phytochem India Pvt Ltd
进行中（未招募）
不适用
Safety and Efficacy of Cariprazine as an Adjunctive to AntidepressantTherapy in Major Depressive DisorderMajor Depressive DisorderEUCTR2011-005179-18-SKForest Research Institute, Inc810
进行中（未招募）
1 期
.MedDRA version: 16.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 16.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2011-005179-18-SEForest Research Institute, Inc819
进行中（未招募）
不适用
Safety and Efficacy of Cariprazine as an Adjunctive to AntidepressantTherapy in Major Depressive DisorderMajor Depressive DisorderEUCTR2011-005179-18-EEForest Research Institute, Inc810
进行中（未招募）
不适用
Safety and Efficacy of Cariprazine as an Adjunctive to AntidepressantTherapy in Major Depressive DisorderMajor Depressive DisorderEUCTR2011-005179-18-FIForest Research Institute, Inc810